Clovis will submit the data by the end of business Monday. The 12-month average price target assigned to the stock is $92.00, which reflects a potential downside of -7.5% from last closing price. In the past twelve weeks, the net percent change held by company insiders has changed by -4.13%. The 50-day moving average is $96.59 and the 200 day moving average is recorded at $89.11.
Advertisement
Historically, Clovis Oncology Incorporated has been trading with a 52 week low of 45.50 and a 52 week of high 116.75.
AstraZeneca’s drug, Tagrisso, is expected to generate $1.1 billion in sales in 2020, according to Thomson Reuters Cortellis.
Clovis Oncology, Inc. (NASDAQ:CLVS) rose 0.02% or 0.02 points on Friday and made its way into the gainers of the day. During the same period in the previous year, the company earned ($1.17) EPS.
On the ratings front, Clovis Oncology has been the subject of a number of recent research reports.
In other news, CFO Erle T. Mast sold 3,000 shares of the company’s stock in a transaction dated Tuesday, September 1st. The current low coincides with March 11, 2013 low at $26.33. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. It’s shares gained modestly, up 2.76% up in pre-market trading. The stock was sold at an average price of $93.04, for a total value of $372,160.00. The disclosure for this sale can be found here.
Clovis’s shares slumped 69 percent in premarket trading on Monday.
Earlier this month, Stifel analysts raised their target price to $140 from around $99.22, writing in a note that everything was moving in a positive direction for Clovis. Out of 4 analysts who cover the stock, 3 suggest a Buy rating and one recommends to Hold the stock.
Rociletinib is the company’s novel, oral, targeted covalent (irreversible) mutant-selective inhibitor of EGFR in development for the treatment of NSCLC in patients with initial activating EGFR mutations, as well as the dominant resistance mutation T790M.
Advertisement
Clovis Oncology Inc is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional worldwide markets.
